FIGURE

Fig. 2

ID

ZDB-FIG-230424-22

Publication

Yang et al., 2023 - FGFR4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling

Other Figures

All Figure Page

Back to All Figure Page

Fig. 2

Elevated EZH2 levels lead to antagonism of HCC against FGFR4 inhibitors. A Western blot analysis of EZH2 expression in HepG2 cells transfected with empty vector control (Con), FLAG-EZH2 (EZH2-Ov) and EZH2-siRNAs (EZH2-siRNA1 and 2). B Cell viability of HepG2 cells transfected with empty vector control (Con), FLAG-EZH2 (EZH2-Ov) and EZH2-siRNAs (EZH2-siRNA1 and 2) was evaluated by the CCK-8 following increasing concentrations of Roblitinib treatment for 48 h. Data are presented as mean � SEM (n = 3). C Crystal violet staining of HepG2 and Huh7 cell lines transfected with empty vector control (Con), FLAG-EZH2 (EZH2-Ov) and EZH2-siRNAs (EZH2-Kd) following Roblitinib treatment for 48 h. Scale bars: 1 cm. D EdU assays of HepG2 cells transfected with empty vector control (Con), FLAG-EZH2 (EZH2-Ov) and EZH2-siRNAs (EZH2-Kd) following Roblitinib treatment for 48 h. Scale bars: 100 ?m. E Measurement of the cell numbers in (D). Data are presented as mean � SEM (n = 3, two-way ANOVA with Sidak?s multiple comparison test, ***p < 0.001, ****p < 0.0001, ns, no significance). F Dose responses of zebrafish KRAS^G12V+/EZH2⁺ (top) and KRAS^G12V+ (bottom) HCC primary tumors treated with Roblitinib for 72 h. Scale bars: 100 ?m. G Measurement of the tumor sizes in (F). Data are presented as mean � SEM (n = 15, two-way ANOVA with Sidak?s multiple comparison test, *p < 0.05, ns, no significance)

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ J. Exp. Clin. Cancer Res.